|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Peroxidase-like properties of Ruthenium nanoframes显示文摘This work reports the inherent peroxidase-like properties of Ruthenium(Ru) nanoframes. After templating with Palladium(Pd) seeds, Ru nanoframes with an octahedral shape, average edge length of 6.2 nm, and thickness of 1.8 nm were synthesized in high purity([95 %) and good uniformity. Using the oxidation of 3,30,5,50-tetramethylbenzidine(TMB) by H2O2 as a model catalytic reaction, the Ru frames were demonstrated to be approximately three times more active than natural peroxidases in catalyzing the formation of colored products. As compared to their natural counterparts, Ru frames have a stronger binding affinity to TMB as well as a weaker binding affinity to hydrogen peroxide during the catalysis. The Ru frames as peroxidase mimics proved to be chemically and thermally stable. This work represents the first demonstration of Ru nanostructure-based peroxidase mimics and is therefore expected to inspire future research on bio-applications of Ru nanomaterials. | Haihang Ye Jacob Mohar Qingxiao Wang Massimo Catalano Moon J.Kim Xiaohu Xia | 2016 | Science Bulletin2016，61，22： | 3 |
| 2 | SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats显示文摘 | Manuela Aragno Chiara E. Tomasinelli Ilenia Vercellinatto Maria G. Catalano Massimo Collino Roberto Fantozzi Oliviero Danni Giuseppe Boccuzzi | 2009 | Free Radical Biology and Medicine2009，，7： | 1 |
| 3 | Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging显示文摘 | Michele Martino Gianmaria Filippis Adriano Santis Daniel Geiger Maurizio Monte Concetta Valentina Lombardo Massimo Rossi Stefano Ginanni Corradini Gianluca Mennini Carlo Catalano | 2013 | European Radiology2013，，4： | 1 |
| 4 | Phase II study of paclitaxel in pretreated advanced gastric cancer显示文摘 | Stefano Cascinu Francesco Graziano Nadia Cardarelli Massimo Marcellini Paolo Giordani Ettore Tito Menichetti Giuseppina Catalano | 1998 | Anti-Cancer Drugs1998，，4： | 1 |
| 5 | Impact of Primary Coronary Angioplasty Delay on Myocardial Salvage, Infarct Size, and Microvascular Damage in Patients With ST-Segment Elevation Myocardial Infarction显示文摘 | Marco Francone Chiara Bucciarelli-Ducci Iacopo Carbone Emanuele Canali Raffaele Scardala Francesca A. Calabrese Gennaro Sardella Massimo Mancone Carlo Catalano Francesco Fedele Roberto Passariello Jan Bogaert Luciano Agati | 2009 | Journal of the American College of Cardiology2009，，23： | 1 |
| 6 | Locoregional therapy and systemic cetuximab to treat colorectal liver metastases显示文摘AIM: To investigate efficacy and safety of second-line treatment with irinotecan-loaded drug-eluting beads(DEBIRI) and cetuximab(DEBIRITUX) of unresectable colorectal liver metastases.METHODS: Patients with the following characteristics were included in the study: unresectable hepatic metastases from colorectal carcinoma(CRC-LM), progression after first line chemotherapy(any type of chemotherapeutic drug and combination was allowed), second line treatment(mandatory), which included for each patient(unregarding the KRas status) two cycles of DEBIRI(using 100-300 μm beads loaded with irinotecan at a total dose 200 mg) followed by 12 cycles of cetuximab that was administered weekly at a first dose of 400 mg/m2 and then 250 mg/m2; good performance status(0-2) and liver functionality(alanine aminotransferase and gamma-glutamyl transferase not exceeding three times the upper limit of normal, total bilirubin not exceeding 2.5 mg/m L). Data were collected retrospectively and included: tumor response(evaluated monthly for 6 mo then every 3 mo), overall response rate(ORR), KRas status, type and intensity of adverse events(G according to the Common Terminology Criteria for Adverse Events v3.0, CTCAE), overall survival(OS) and progression free survival(PFS).RESULTS: Forty consecutive cases of CRC hepatic metastases were included in the study. Median duration of DEBIRITUX was 4.4 mo(range, 4.0-6.5). Sixteen patients(40%) received the planned 2 cycles of DEBIRI and an average of 10 cetuximab cycles. ORR of the whole sample was 50%, in particular 4 patients were complete responders(10%) and 16(40%) partial responders. The most observed side effects(G2) were: post-embolization syndrome(30%), diarrhea(25%), skin rushes(38%) and asthenia(35%). The retrospective evaluation of KRas status(24 wild type, 16 mutated) showed that the group of patients with wild type KRas had ORR significantly higher than mutant KRas. Median follow-up was 29 mo(8-48 range); median PFS was 9.8 mo and OS was 20.4 mo. Future randomized trials are required in this setting to establish a role for DEBIRITUX compared with systemic chemotherapy.CONCLUSION: DEBIRITUX seems to be efficacious after first line chemotherapy for the treatment of unresectable CRC-LM. | Giammaria Fiorentini Camillo Aliberti Donatella Sarti Paolo Coschiera Massimo Tilli Luca Mulazzani Paolo Giordani Francesco Graziano Alfonso Marqués Gonzalez Raul García Marcos Fernando Gómez Mugnoz Maurizio Cantore Stefano Ricci Vincenzo Catalano Andrea Mambrini | 2015 | World Journal of Gastrointestinal Oncology2015，7，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员